These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19660439

  • 1. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
    Nakagawa S, Masuda S, Nishihara K, Inui K.
    Biochem Pharmacol; 2010 Jan 01; 79(1):67-76. PubMed ID: 19660439
    [Abstract] [Full Text] [Related]

  • 2. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 3. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury.
    Nakagawa S, Nishihara K, Inui K, Masuda S.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):143-54. PubMed ID: 23022334
    [Abstract] [Full Text] [Related]

  • 4. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ, Lin TY.
    Ai Zheng; 2007 Dec 05; 26(12):1397-403. PubMed ID: 18076811
    [Abstract] [Full Text] [Related]

  • 5. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.
    Am J Physiol Renal Physiol; 2009 Dec 05; 297(6):F1597-605. PubMed ID: 19776171
    [Abstract] [Full Text] [Related]

  • 6. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 05; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 7. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats.
    Nishihara K, Masuda S, Nakagawa S, Yonezawa A, Ichimura T, Bonventre JV, Inui K.
    Am J Physiol Renal Physiol; 2010 Apr 05; 298(4):F923-34. PubMed ID: 20071461
    [Abstract] [Full Text] [Related]

  • 8. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
    Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL.
    J Dermatol Sci; 2009 Nov 05; 56(2):82-8. PubMed ID: 19699613
    [Abstract] [Full Text] [Related]

  • 9. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.
    Expert Rev Anticancer Ther; 2009 Jun 05; 9(6):705-17. PubMed ID: 19496707
    [Abstract] [Full Text] [Related]

  • 10. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL.
    Kidney Blood Press Res; 2007 Jun 05; 30(4):253-9. PubMed ID: 17596700
    [Abstract] [Full Text] [Related]

  • 11. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F, Rovira J, Carreras J, Arellano EM, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Brunet M, Campistol JM.
    J Am Soc Nephrol; 2007 Oct 05; 18(10):2653-60. PubMed ID: 17804674
    [Abstract] [Full Text] [Related]

  • 12. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
    Duman S, Bozkurt D, Sipahi S, Sezak M, Ozkan S, Ertilav M, Sen S, Ok E.
    Adv Perit Dial; 2008 Oct 05; 24():104-10. PubMed ID: 18986012
    [Abstract] [Full Text] [Related]

  • 13. Everolimus, a promising medical therapy for coronary heart disease?
    Jia L, Hui RT.
    Med Hypotheses; 2009 Aug 05; 73(2):153-5. PubMed ID: 19375241
    [Abstract] [Full Text] [Related]

  • 14. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
    Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB.
    Horm Metab Res; 2009 Sep 05; 41(9):697-702. PubMed ID: 19424940
    [Abstract] [Full Text] [Related]

  • 15. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov 05; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 16. Apoptosis and treatment of chronic allograft nephropathy with everolimus.
    Lutz J, Zou H, Liu S, Antus B, Heemann U.
    Transplantation; 2003 Aug 15; 76(3):508-15. PubMed ID: 12923436
    [Abstract] [Full Text] [Related]

  • 17. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
    Zhuo L, Cai G, Liu F, Fu B, Liu W, Hong Q, Ma Q, Peng Y, Wang J, Chen X.
    Mech Ageing Dev; 2009 Oct 15; 130(10):700-8. PubMed ID: 19698731
    [Abstract] [Full Text] [Related]

  • 18. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease.
    Edelstein CL.
    Clin J Am Soc Nephrol; 2008 Jul 15; 3(4):1219-26. PubMed ID: 18587045
    [Abstract] [Full Text] [Related]

  • 19. Selective clearance of macrophages in atherosclerotic plaques by autophagy.
    Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR.
    J Am Coll Cardiol; 2007 Feb 13; 49(6):706-15. PubMed ID: 17291937
    [Abstract] [Full Text] [Related]

  • 20. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.
    N Engl J Med; 2010 Aug 26; 363(9):830-40. PubMed ID: 20581392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.